GS/GOGAT cycle. by Alejandro Torres-Sánchez (713429)

Response gain control by ACh. by Shogo Soma (429657)

“…Gray circles indicate facilitated and suppressed cells whose C₅₀ were decreased or increased by more than 1 SD from the population average, respectively (C, facilitated cells, <i>n</i> = 4; D, suppressed cells, <i>n</i> = 7). …”

Degree of sampling of SILAC peptide pairs by Lyris MF de Godoy (23671)

“…<p><b>Copyright information:</b></p><p>Taken from "Status of complete proteome analysis by mass spectrometry: SILAC labeled yeast as a model system"</p><p>Genome Biology 2006;7(6):R50-R50.</p><p>Published online 19 Jun 2006</p><p>PMCID:PMC1779535.…”

Outcome of environmental surveys by hospital ward. by Antonella Felice (6934226)

“…<p>Each survey with at least one positive sample was assigned a “positive” outcome and was further classified into low (100 ≤ CFUl⁻¹ ≤ 1,000), medium (1,000 ≤ CFUl⁻¹ ≤ 10,000) and high (>10,000 CFUl⁻¹) risk based on the highest contamination found. …”

Estimated median (and inter-quartile range) probability (%) of developing life-long immunity after HPV infection clearance by HPV type. by Iacopo Baussano (234638)

“…<div><p>As the probability decreases from 50% to 0%, HPV infections are increasingly more likely to be cleared without developing immunity, i.e. increasingly characterized by a predominant SIS clearance pattern. …”

Effect of azurin in FAK-Src signaling. by Nuno Bernardes (435240)

“…<p>Azurin at 50 µM and 100 µM decreased phosphorylation levels of FAK Y397 and Src Y416 in both MCF-7/AZ.Pcad and SUM149 breast cancer cells, but not Akt S473, in a dose-dependent manner. …”

The epidemiology of dengue disease in the Philippines, 2000–2011. by Lulu Bravo (655497)

“…Overall, the CFR was in the range 0.5–1.2 per 100 cases and decreased after 2005. Using available data* from the DoH <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-Department1" target="_blank">[5]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-Department3" target="_blank">[25]</a>–<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-Department7" target="_blank">[29]</a> and the WHO <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-World1" target="_blank">[6]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-LeeSuy1" target="_blank">[16]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-World4" target="_blank">[20]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-World5" target="_blank">[21]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-World6" target="_blank">[30]</a>–<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0003027#pntd.0003027-World8" target="_blank">[32]</a>. …”

Mitomycin C treatment induces production of bacteriophage particles in 17978. by Janelle M. Hare (548460)

“…<p>(A) Overnight LB cultures of 17978 cells were diluted into fresh LB medium and grown for 0.75 hours before addition of 2 μg/mL MMC. …”

Cytotoxicity of U87MG cells treated with RGD peptide or the combination of PTX and RGD peptide was quantified using MTT assay. by Ming-Wei Chang (321745)

“…(B) Cell viability of E[c(RGDyK)]₂ peptides or combination pre-treated by 10 nM PTX in U87MG cells. Cell viability was decreased at 100 µM c(RGDyK) or E[c(RGDyK)]₂ peptide. …”

Characterization of <i>Acinetobacter</i> type IVa pilus components. by Ruben Iruegas (6203684)

“…Taxa are ordered according to increasing phylogenetic distance to <i>A</i>. <i>baumannii</i> using the information provided in [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1010646#pgen.1010646.ref021" target="_blank">21</a>] and [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1010646#pgen.1010646.ref100" target="_blank">100</a>]. …”

Increased aggregation propensity enhances Pept-in antimicrobial potency by promoting Pept-in accumulation and IB formation. by Guiqin Wu (760045)

“…<b>C:</b> Time dependence of pFTAA (0.5 μM) fluorescence intensity of P2 derivatives (50 μM) in the presence of polyP (0.5 mM) (n = at least 6). …”

ET-1 upregulated MMP-1 and MMP-13 expression and downregulated TIMP-1 release. by Wei Yuan (64653)

“…<p>Confluent CECs in six-well plates were cultured in serum-free medium for 12 hours and then treated with ET-1 (0–100 nM) for 36 hours. ET-1 increased the release of MMP-1 and MMP-13, but decreased the production of TIMP-1 in a dose-dependent pattern as shown by ELISA assay. …”

Non-clinical surveys by category of settings. by Antonella Felice (6934226)

“…<p>Each survey with at least one positive sample was assigned a “positive” outcome and was further classified into low (100 ≤ CFUl⁻¹ ≤ 1,000), medium (1,000 ≤ CFUl⁻¹ ≤ 10,000) and high (>10,000 CFUl⁻¹) risk based on the highest contamination found. …”

Riociguat prevents hyperoxia-impaired alveolarization. by Keyur Donda (5497400)

“…<p>(<b>A</b>) H & E stained lung histology. Hyperoxia exposure in the presence of placebo decreased radial alveolar count (RAC) (<b>B</b>) and increased mean linear intercept (MLI) (<b>C</b>) as compared with normoxia. …”

Dfos increases Rho1-GTP, the formin Diaphanous and actin at the cortex through Cher and TM4SF. by Vera Belyaeva (11914218)

“…Line length approximately 8 μm. Blue lines indicate mean GFP intensity on the membrane and in cytoplasm. …”

Table_1_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

“…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m²) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”

Data Sheet 1_Effect of high intakes of protein-only and carbohydrate-only on plasma metabolites and hormones, in addition to nitrogen excretion.xlsx by Matthieu Clauss (9769343)

“…</p>Methods<p>Fourteen young, healthy, moderate-to-well-trained participants (VO_2max 50.6 ± 2.9 mL·kg^-1·min^-1; mean ± SEM) reported in the morning after an overnight fast. …”

Table1_Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19.DOCX by Elena Campello (11953730)

“…The following EVs were measured: endothelium-, platelet-, leukocyte-derived, bearing tissue factor (TF)+, angiotensin-converting enzyme (ACE2)+, platelet-derived growth factor receptor-β (PDGF-β)+ and SARS-CoV-2-nucleoprotein (NP)+. 91 patients were recruited for baseline EV analysis (mean age 67 ± 14 years, 50.5% male) and 48 underwent the longitudinal evaluation. …”

Table_2_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

“…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m²) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-co... by Tadao Akizawa (316095)

“…Adverse events were observed in 30%–50% of patients (all groups). Incidence of adverse events was similar among all groups except for decreased calcium, which occurred more frequently in the evocalcet 2 mg and cinacalcet groups.…”